Summary

The single-use bioreactors market is projected to reach USD 9.58 billion by 2031 from an estimated USD 5.43 billion in 2026, at a CAGR of 12.0% during the forecast period of 2026 to 2031. Market growth is primarily supported by expanding biologics and biosimilar production, rising vaccine manufacturing, increasing outsourcing to CDMOs, and greater adoption of flexible bioprocessing technologies. The growing use of single-use systems in monoclonal antibody, recombinant protein, viral vector, and cell & gene therapy manufacturing is further accelerating demand. Their lower capital requirements, reduced cleaning validation, faster product changeovers, and suitability for multiproduct facilities are expected to support market expansion.

By application, the bioproduction segment accounted for the largest share of the market in 2025.
In 2025, the bioproduction segment accounted for the largest share of the global single-use bioreactors market. These systems are extensively used for the commercial and clinical production of monoclonal antibodies, vaccines, recombinant proteins, biosimilars, viral vectors, and other biologics. The segment’s leading position is supported by increasing demand for biologics, expansion of global manufacturing capacity, and growing adoption of scalable single-use platforms across pharmaceutical and biotechnology companies and CDMOs. Their ability to reduce contamination risks, shorten turnaround times, and support batch, fed-batch, and perfusion processes further strengthens their use in bioproduction applications.

The monoclonal antibodies segment accounted for a major share of the single-use bioreactors market in 2025.
The single-use bioreactors market is categorized by molecule type into monoclonal antibodies, vaccines, cell & gene therapy, and therapeutic proteins & peptides. The monoclonal antibodies segment accounted for the largest market share in 2025, supported by the substantial number of approved products, extensive development pipelines, and continued expansion of commercial manufacturing capacity. Monoclonal antibody production requires scalable and tightly controlled mammalian cell culture processes, creating sustained demand for stirred-tank single-use bioreactors, bags, assemblies, sensors, and fluid-management components. Their suitability for batch, fed-batch, and intensified processing further supports adoption across pharmaceutical and biotechnology companies and CDMOs.

The Asia Pacific region is expected to experience the highest CAGR in the single-use bioreactors market from 2026 to 2031.
The single-use bioreactors market is divided into North America, Europe, Asia Pacific, Latin America, the Middle East, and Africa. Asia Pacific is expected to register the fastest growth during the forecast period, driven by expanding biologics and biosimilar production, increasing vaccine manufacturing, rising CDMO capacity, and greater investment in domestic biopharmaceutical infrastructure. China, India, Japan, South Korea, and Australia are strengthening their upstream processing capabilities through new facilities, capacity additions, and wider adoption of modular and flexible production technologies. Government support for local manufacturing and the growth of cell & gene therapy activity are further accelerating regional demand.

The primary interviews conducted for this report can be categorized as follows:

・By Respondent: Supply Side (80%) and Demand Side (20%)
・By Designation: Managers (45%), CXOs & Directors (30%), and Executives (25%)
・By Region: North America (40%), Europe (25%), Asia Pacific (25%), Latin America (5%), and the Middle East & Africa (5%)

Sartorius AG (Germany), Danaher Corporation (US), Thermo Fisher Scientific Inc. (US), Merck KGaA (Germany), Avantor, Inc. (US), Repligen Corporation (US), Getinge AB (Sweden), Eppendorf SE (Germany), Parker Hannifin Corporation (US), Entegris (US), Saint-Gobain (France), Corning Incorporated (US), Lonza (Switzerland), TECNIC Process Equipment Manufacturing, S.L. (Spain), ZACROS Corporation (Japan), Adolf Kühner AG (Switzerland), OmniBRx Biotechnologies Pvt Ltd. (India), New Horizon Biotechnology, Inc. (US), PBS Biotech, Inc. (US), bbi-biotech GmbH (Germany), ABEC, Inc. (US), Esco Lifesciences Group (US), Distek, Inc. (US), SATAKE MultiMix Corporation (Japan), Cell Culture Company, LLC (US), MicroDigital Co., Ltd. (South Korea), BIONET (Spain), Meissner Filtration Products, Inc. (US), Solida Biotech GmbH (Germany), G&G Technologies, Inc. (US), PharmNXT Biotech (India), and Tofflon Life Science Co., Ltd. (China) are some of the key companies offering single-use bioreactors solutions.

Research Coverage
This research report categorizes the single-use bioreactors market by product (single-use bioreactor systems, single-use bags, single-use assemblies, and other products), type (stirred-tank single-use bioreactors, wave-induced single-use bioreactors, fixed-bed single-use bioreactors, bubble-column single-use bioreactors, and other single-use bioreactors), cell type (mammalian cells, bacterial cells, yeast cells, and other cells), molecule type (monoclonal antibodies, vaccines, cell & gene therapy, and therapeutic proteins & peptides), process mode (fed-batch, batch, and perfusion/continuous), application (bioproduction, process development, and research & development), end user (pharmaceutical and biotechnology companies, CROs & CMOs, and academic & research institutes), and region (North America, Europe, Asia Pacific, Latin America, Middle East, and Africa).
The scope of the report provides detailed information on major factors such as drivers, challenges, opportunities, and restraints that influence the growth of the single-use bioreactors market. A comprehensive analysis of key industry players has been conducted to provide insights into their business overviews, product portfolios, and key strategies, including collaborations, partnerships, expansions, agreements, acquisitions, and recent developments in the single-use bioreactors market.
Key Benefits of Buying the Report
This report offers a comprehensive overview of the single-use bioreactors market. It aims to assess the market size and future growth opportunities across various segments. The report also features an in-depth competitive analysis of the major market players, including their company profiles, recent developments, and key market strategies
The report provides insights into the following pointers:
・Analysis of key drivers (rising adoption of flexible sub platforms among CDMOs, CMOs, and SMEs, operational advantages over conventional bioreactors, reduced upfront capital investment, reduced water and energy consumption, and expansion of biologics and biosimilar manufacturing demand), restraints (concerns related to extractables and leachables, regulatory and compliance requirements for SUB implementation, and impact of PFAS restrictions on product development), opportunities (untapped growth potential in emerging biomanufacturing economies and shift toward hybrid biomanufacturing), and challenges (lack of standardization, waste disposal burden and sustainability pressure, and risk of SU bag leakage and integrity failure) influencing the growth of the market.
・Product Development/Innovation: Detailed insights on newly launched products of the single-use bioreactors market.
・Market Development: Comprehensive information about lucrative markets; the report analyzes the market across varied regions.
・Market Diversification: Exhaustive information about new products, untapped geographies, recent developments, and investments in the single-use bioreactors market.
・Competitive Assessment: In-depth assessment of market shares, growth strategies, and product offerings of leading players such as Sartorius AG (Germany), Danaher Corporation (US), Thermo Fisher Scientific Inc. (US), Merck KGaA (Germany), Avantor, Inc. (US), Repligen Corporation (US), Getinge AB (Sweden), Eppendorf SE (Germany), Parker Hannifin Corporation (US), Entegris (US), Saint-Gobain (France), Corning Incorporated (US), Lonza (Switzerland), TECNIC Process Equipment Manufacturing, S.L. (Spain), ZACROS Corporation (Japan), Adolf Kühner AG (Switzerland), OmniBRx Biotechnologies Pvt Ltd. (India), New Horizon Biotechnology, Inc. (US), PBS Biotech, Inc. (US), bbi-biotech GmbH (Germany), ABEC, Inc. (US), Esco Lifesciences Group (US), Distek, Inc. (US), SATAKE MultiMix Corporation (Japan), Cell Culture Company, LLC (US), MicroDigital Co., Ltd. (South Korea), BIONET (Spain), Meissner Filtration Products, Inc. (US), Solida Biotech GmbH (Germany), G&G Technologies, Inc. (US), PharmNXT Biotech (India), and Tofflon Life Science Co., Ltd. (China).

ページTOPに戻る

Table of Contents

1 INTRODUCTION 42
1.1 STUDY OBJECTIVES 42
1.2 MARKET DEFINITION 42
1.3 STUDY SCOPE 42
1.3.1 MARKET SEGMENTATION & REGIONS COVERED 43
1.3.2 INCLUSIONS & EXCLUSIONS 44
1.3.3 YEARS CONSIDERED 45
1.3.4 CURRENCY CONSIDERED 45
1.4 STAKEHOLDERS 45
1.5 SUMMARY OF CHANGES 46
2 EXECUTIVE SUMMARY 47
2.1 MARKET HIGHLIGHTS & KEY INSIGHTS 47
2.2 KEY MARKET PARTICIPANTS: MAPPING OF STRATEGIC DEVELOPMENTS 49
2.3 DISRUPTIVE TRENDS IN SINGLE-USE BIOREACTORS MARKET 50
2.4 HIGH-GROWTH SEGMENTS 51
2.5 REGIONAL SNAPSHOT: MARKET SIZE, GROWTH RATE, AND FORECAST 52
3 PREMIUM INSIGHTS 53
3.1 GLOBAL SINGLE-USE BIOREACTORS MARKET SNAPSHOT 53
3.2 NORTH AMERICA: SINGLE-USE BIOREACTORS MARKET,
BY PRODUCT AND COUNTRY, 2025 54
3.3 SINGLE-USE BIOREACTORS MARKET: GEOGRAPHIC GROWTH OPPORTUNITIES 55
3.4 SINGLE-USE BIOREACTORS MARKET SHARE, BY END USER, 2026 VS. 2031 (%) 56
4 MARKET OVERVIEW 57
4.1 INTRODUCTION 57
4.2 MARKET DYNAMICS 57
4.2.1 DRIVERS 58
4.2.1.1 Rising adoption of flexible SUB platforms among CDMOs,
CMOs, and SMEs 58
4.2.1.2 Operational advantages over conventional bioreactors 59
4.2.1.3 Reduced upfront capital investment 60
4.2.1.4 Reduced water and energy consumption 61
4.2.1.5 Expansion of biologics and biosimilar manufacturing demand 62
4.2.2 RESTRAINTS 64
4.2.2.1 Concerns related to extractables and leachables 64
4.2.2.2 Regulatory and compliance requirements for SUB implementation 64
4.2.2.3 Impact of PFAS restrictions on product development 65
4.2.3 OPPORTUNITIES 66
4.2.3.1 Untapped growth potential in emerging biomanufacturing economies 66
4.2.3.2 Shift towards hybrid biomanufacturing 67
4.2.4 CHALLENGES 67
4.2.4.1 Lack of standardization 67
4.2.4.2 Waste disposal burden and sustainability pressure 68
4.2.4.3 Risk of SU bag leakage and integrity failure 69
4.3 UNMET NEEDS & WHITE SPACES 70
4.4 INTERCONNECTED MARKETS & CROSS-SECTOR OPPORTUNITIES 70
4.5 STRATEGIC MOVES BY TIER-1/2/3 PLAYERS 71
5 INDUSTRY TRENDS 72
5.1 PORTER’S FIVE FORCES ANALYSIS 72
5.1.1 BARGAINING POWER OF SUPPLIERS 73
5.1.2 BARGAINING POWER OF BUYERS 73
5.1.3 THREAT OF NEW ENTRANTS 73
5.1.4 THREAT OF SUBSTITUTES 73
5.1.5 INTENSITY OF COMPETITIVE RIVALRY 74
5.2 MACROECONOMIC OUTLOOK 74
5.2.1 INTRODUCTION 74
5.2.2 GDP TRENDS & FORECAST 74
5.2.3 TRENDS IN GLOBAL SINGLE-USE BIOREACTORS INDUSTRY 75
5.3 VALUE CHAIN ANALYSIS 76
5.4 ECOSYSTEM ANALYSIS 77
5.5 PRICING ANALYSIS 80
5.5.1 AVERAGE SELLING PRICE TREND OF KEY SINGLE-USE BIOREACTOR PRODUCTS, BY KEY PLAYER, 2023–2025 81
5.5.2 AVERAGE SELLING PRICE TREND OF KEY SINGLE-USE BIOREACTOR PRODUCTS, BY REGION, 2023–2025 83
5.6 TRADE ANALYSIS 85
5.6.1 IMPORT SCENARIO (HS CODE 841989) 85
5.6.2 EXPORT SCENARIO (HS CODE 841989) 87
5.7 KEY CONFERENCES & EVENTS, 2026–2027 89
5.8 TRENDS/DISRUPTIONS IMPACTING CUSTOMERS’ BUSINESSES 89
5.9 INVESTMENT & FUNDING SCENARIO 91
5.9.1 VC/PRIVATE EQUITY INVESTMENT TRENDS & STARTUP LANDSCAPE 91
5.10 IMPACT OF 2025 US TARIFFS ON SINGLE-USE BIOREACTORS MARKET 92
5.10.1 INTRODUCTION 92
5.10.2 KEY TARIFF RATES 92
5.10.3 PRICE IMPACT ANALYSIS 93
5.10.4 IMPACT ON COUNTRIES/REGIONS 94
5.10.4.1 US 94
5.10.4.2 Europe 94
5.10.4.3 Asia Pacific 94
5.10.5 IMPACT ON END-USE INDUSTRIES 95
5.10.5.1 Pharmaceutical & biotechnology companies 95
5.10.5.2 CROs & CMOs 96
5.10.5.3 Academic & research institutes 96
6 TECHNOLOGICAL ADVANCEMENTS, AI-DRIVEN IMPACT,
PATENTS, AND INNOVATIONS 97
6.1 TECHNOLOGY ANALYSIS 97
6.1.1 KEY EMERGING TECHNOLOGIES 97
6.1.1.1 Fermentation 97
6.1.1.2 Continuous bioprocessing 97
6.1.1.3 3D cell culture 98
6.1.2 COMPLEMENTARY TECHNOLOGIES 98
6.1.2.1 Automation & control 98
6.1.2.2 Data analytics & machine learning 98
6.1.3 ADJACENT TECHNOLOGIES 99
6.1.3.1 Filtration 99
6.1.3.2 Cell separation 99
6.2 TECHNOLOGY/PRODUCT ROADMAP 99
6.3 PATENT ANALYSIS 100
6.3.1 TOP APPLICANTS/OWNERS (COMPANIES) FOR SINGLE-USE BIOREACTOR PATENTS 100
6.4 FUTURE APPLICATIONS 103
6.5 IMPACT OF AI/GEN AI ON SINGLE-USE BIOREACTORS MARKET 104
6.5.1 BEST PRACTICES IN SINGLE-USE BIOREACTORS WORKFLOW 105
6.5.2 CASE STUDIES OF AI IMPLEMENTATION IN SINGLE-USE BIOREACTORS MARKET 105
6.5.3 INTERCONNECTED ADJACENT ECOSYSTEMS & IMPACT ON MARKET PLAYERS 106
6.5.4 CLIENTS’ READINESS TO ADOPT GENERATIVE AI IN SINGLE-USE BIOREACTORS MARKET 106
7 SUSTAINABILITY & REGULATORY LANDSCAPE 107
7.1 REGIONAL REGULATIONS & COMPLIANCE 107
7.1.1 REGULATORY BODIES, GOVERNMENT AGENCIES,
AND OTHER ORGANIZATIONS 107
7.1.2 REGULATORY FRAMEWORK 110
7.1.2.1 North America 110
7.1.2.2 Europe 111
7.1.2.3 Asia Pacific 111
7.1.2.4 Rest of the World 111
7.1.3 INDUSTRY STANDARDS 111
7.2 SUSTAINABILITY INITIATIVES 112
7.3 SUSTAINABILITY IMPACT & REGULATORY POLICY INITIATIVES 113
7.4 CERTIFICATIONS, LABELING, AND ECO-STANDARDS 113
8 CUSTOMER LANDSCAPE & BUYER BEHAVIOR 115
8.1 DECISION-MAKING PROCESS 115
8.2 BUYER STAKEHOLDERS & BUYING EVALUATION CRITERIA 115
8.2.1 KEY STAKEHOLDERS IN BUYING PROCESS 115
8.2.2 KEY BUYING CRITERIA, BY END USER 117
8.3 ADOPTION BARRIERS & INTERNAL CHALLENGES 119
8.4 UNMET NEEDS FROM VARIOUS END-USE INDUSTRIES 119
8.5 MARKET PROFITABILITY 119
9 SINGLE-USE BIOREACTORS MARKET, BY PRODUCT 120
9.1 INTRODUCTION 121
9.2 SINGLE-USE BIOREACTOR SYSTEMS 121
9.2.1 ≤10 L BIOREACTORS 126
9.2.1.1 High-throughput process development and scale-down studies to support market growth 126
9.2.2 11–100 L BIOREACTORS 129
9.2.2.1 Increasing pilot-scale and clinical manufacturing to support market growth 129
9.2.3 101–500 L BIOREACTORS 133
9.2.3.1 Flexible scale-up from clinical to early commercial production to propel market growth 133
9.2.4 501–1,500 L BIOREACTORS 136
9.2.4.1 Expanding late-stage and commercial biologics capacity to support market growth 136
9.2.5 >1,500 L BIOREACTORS 140
9.2.5.1 Large-scale single-use commercialization to strengthen market position 140
9.3 SINGLE-USE BAGS 143
9.3.1 2D SINGLE-USE BAGS 146
9.3.1.1 Low-volume flexibility and expanding cell therapy applications to support market growth 146
9.3.2 3D SINGLE-USE BAGS 150
9.3.2.1 Large-volume biologics production to support market growth 150
9.4 SINGLE-USE ASSEMBLIES 153
9.4.1 INCREASING ADOPTION OF CLOSED FLUID PATHS TO SUPPORT MARKET GROWTH 153
9.5 OTHER PRODUCTS 156
10 SINGLE-USE BIOREACTORS MARKET, BY TYPE 160
10.1 INTRODUCTION 161
10.2 STIRRED-TANK SINGLE-USE BIOREACTORS 161
10.2.1 BROAD SCALABILITY AND COMPATIBILITY WITH INTENSIFIED CELL CULTURE TO SUPPORT MARKET GROWTH 161
10.3 WAVE-INDUCED SINGLE-USE BIOREACTORS 165
10.3.1 INCREASING ADOPTION IN CELL THERAPY AND SEED-TRAIN APPLICATIONS TO SUPPORT MARKET GROWTH 165
10.4 FIXED-BED SINGLE-USE BIOREACTORS 169
10.4.1 HIGH-DENSITY ADHERENT CELL AND VIRAL VECTOR PRODUCTION TO DRIVE FASTEST MARKET GROWTH 169
10.5 BUBBLE-COLUMN SINGLE-USE BIOREACTORS 173
10.5.1 IMPELLER-FREE MIXING AND EXPANDING MICROBIAL APPLICATIONS TO SUPPORT MARKET GROWTH 173
10.6 OTHER SINGLE-USE BIOREACTORS 176
11 SINGLE-USE BIOREACTORS MARKET, BY MOLECULE TYPE 180
11.1 INTRODUCTION 181
11.2 MONOCLONAL ANTIBODIES 181
11.2.1 EXPANDING THERAPEUTIC PIPELINES AND BIOSIMILAR PRODUCTION TO SUPPORT SEGMENT DOMINANCE 181
11.3 VACCINES 185
11.3.1 EXPANDING VACCINE PIPELINES AND FLEXIBLE MANUFACTURING REQUIREMENTS TO SUPPORT MARKET GROWTH 185
11.4 CELL & GENE THERAPY 188
11.4.1 EXPANDING ADVANCED THERAPY PIPELINES AND MANUFACTURING INVESTMENTS TO SUPPORT MARKET GROWTH 188
11.5 THERAPEUTIC PROTEINS & PEPTIDES 192
11.5.1 INCREASING DEMAND FOR RECOMBINANT PROTEINS AND PEPTIDE THERAPEUTICS TO SUPPORT MARKET GROWTH 192
12 SINGLE-USE BIOREACTORS MARKET, BY CELL TYPE 196
12.1 INTRODUCTION 197
12.2 MAMMALIAN CELLS 197
12.2.1 HIGH DEMAND FOR COMPLEX BIOLOGICS TO SUPPORT SEGMENT DOMINANCE 197
12.3 BACTERIAL CELLS 201
12.3.1 EXPANDING PLASMID DNA AND RECOMBINANT PROTEIN PRODUCTION TO SUPPORT MARKET GROWTH 201
12.4 YEAST CELLS 204
12.4.1 INCREASING USE IN RECOMBINANT PROTEIN AND VACCINE PRODUCTION TO SUPPORT MARKET GROWTH 204
12.5 OTHER CELLS 208
13 SINGLE-USE BIOREACTORS MARKET, BY APPLICATION 212
13.1 INTRODUCTION 213
13.2 BIOPRODUCTION 213
13.2.1 COMMERCIAL BIOLOGICS PRODUCTION AND FLEXIBLE MANUFACTURING CAPACITY TO REINFORCE SEGMENT LEADERSHIP 213
13.3 PROCESS DEVELOPMENT 217
13.3.1 ACCELERATED PROCESS OPTIMIZATION TO DRIVE GROWTH OF PROCESS DEVELOPMENT APPLICATIONS 217
13.4 RESEARCH & DEVELOPMENT 220
13.4.1 GROWING ADOPTION OF INTENSIFIED BIOPROCESSING TO DRIVE FASTEST GROWTH IN PERFUSION-BASED MANUFACTURING 220
14 SINGLE-USE BIOREACTORS MARKET, BY PROCESS MODE 224
14.1 INTRODUCTION 225
14.2 FED-BATCH PROCESS MODE 225
14.2.1 COMMERCIAL BIOLOGICS MANUFACTURING TO CONTINUE TO POSITION FED-BATCH AS LARGEST PROCESS SEGMENT 225
14.3 BATCH PROCESS MODE 229
14.3.1 PROCESS DEVELOPMENT AND SMALL-SCALE BIOLOGICS PRODUCTION TO SUSTAIN DEMAND FOR BATCH PROCESSING 229
14.4 PERFUSION/CONTINUOUS PROCESS MODE 232
14.4.1 GROWING ADOPTION OF INTENSIFIED BIOPROCESSING TO DRIVES FASTEST GROWTH IN PERFUSION-BASED MANUFACTURING 232
15 SINGLE-USE BIOREACTORS MARKET, BY END USER 236
15.1 INTRODUCTION 237
15.2 PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES 237
15.2.1 COMMERCIAL BIOLOGICS PRODUCTION AND FLEXIBLE MANUFACTURING CAPACITY TO REINFORCE SEGMENT LEADERSHIP 237
15.3 CROS & CDMOS 241
15.3.1 BIOLOGICS OUTSOURCING TO DRIVE GROWTH AMONG CROS AND CMOS 241
15.4 ACADEMIC & RESEARCH INSTITUTES 244
15.4.1 EXPANDING LIFE SCIENCE RESEARCH TO CONTINUE TO SUPPORT DEMAND FROM ACADEMIC & RESEARCH INSTITUTES 244
16 SINGLE-USE BIOREACTORS MARKET, BY REGION 248
16.1 INTRODUCTION 249
16.2 NORTH AMERICA 249
16.2.1 US 254
16.2.1.1 US to dominate North American market during study period 254
16.2.2 CANADA 258
16.2.2.1 Public bio­manufacturing investment and advanced-therapy capacity expansion to support market growth 258
16.3 EUROPE 261
16.3.1 GERMANY 265
16.3.1.1 Strong bioprocessing ecosystem and expanding therapeutic pipelines to support market growth 265
16.3.2 UK 269
16.3.2.1 Public funding and advanced-therapy manufacturing to support market growth 269
16.3.3 FRANCE 272
16.3.3.1 Strong bioprocessing supply base and biopharmaceutical investments to support market growth 272
16.3.4 ITALY 276
16.3.4.1 Strong pharmaceutical manufacturing and advanced-therapy capabilities to support market growth 276
16.3.5 SPAIN 280
16.3.5.1 Expanding biotechnology R&D and CDMO capacity to support market growth 280
16.3.6 REST OF EUROPE 283
16.4 ASIA PACIFIC 287
16.4.1 CHINA 293
16.4.1.1 Large biologics pipeline and commercial-scale single-use capacity to drive market growth 293
16.4.2 SOUTH KOREA 297
16.4.2.1 Large-scale CDMO capacity and export-oriented biopharmaceutical industry to support market growth 297
16.4.3 JAPAN 301
16.4.3.1 Biologics pipeline expansion and regenerative medicine commercialization to support market growth 301
16.4.4 INDIA 305
16.4.4.1 Export-oriented biopharmaceutical industry and policy support to drive market growth 305
16.4.5 AUSTRALIA 309
16.4.5.1 Clinical research funding and advanced-therapy manufacturing to support market growth 309
16.4.6 REST OF ASIA PACIFIC 312
16.5 LATIN AMERICA 316
16.5.1 BRAZIL 320
16.5.1.1 Public bioproduction investment and expanding vaccine capabilities to support market growth 320
16.5.2 MEXICO 324
16.5.2.1 Domestic biopharmaceutical capacity expansion to support market growth 324
16.5.3 REST OF LATIN AMERICA 327
16.6 MIDDLE EAST 331
16.6.1 GCC COUNTRIES 335
16.6.1.1 Saudi Arabia 338
16.6.1.1.1 National biotechnology strategy and commercial biopharma capacity to propel market growth 338
16.6.1.2 UAE 342
16.6.1.2.1 Vaccine manufacturing and regulatory ecosystem development to support market growth 342
16.6.1.3 Rest of GCC countries 345
16.6.2 REST OF MIDDLE EAST 348
16.7 AFRICA 352
16.7.1 VACCINE MANUFACTURING LOCALIZATION AND TECHNOLOGY TRANSFER TO SUPPORT MARKET GROWTH 352
17 COMPETITIVE LANDSCAPE 356
17.1 OVERVIEW 356
17.2 KEY PLAYER STRATEGIES/RIGHT TO WIN 356
17.2.1 OVERVIEW OF STRATEGIES ADOPTED BY PLAYERS IN SINGLE-USE BIOREACTORS MARKET 356
17.3 REVENUE ANALYSIS, 2021–2025 358
17.4 MARKET SHARE ANALYSIS, 2025 359
17.5 COMPANY EVALUATION MATRIX: KEY PLAYERS, 2025 361
17.5.1 STARS 361
17.5.2 EMERGING LEADERS 361
17.5.3 PERVASIVE PLAYERS 362
17.5.4 PARTICIPANTS 362
17.5.5 COMPANY FOOTPRINT: KEY PLAYERS, 2025 363
17.5.5.1 Company footprint 363
17.5.5.2 Region footprint 364
17.5.5.3 Product footprint 365
17.5.5.4 Type footprint 366
17.5.5.5 Application footprint 367
17.6 COMPANY EVALUATION MATRIX: STARTUPS/SMES, 2025 368
17.6.1 PROGRESSIVE COMPANIES 368
17.6.2 RESPONSIVE COMPANIES 368
17.6.3 DYNAMIC COMPANIES 368
17.6.4 STARTING BLOCKS 368
17.6.5 COMPETITIVE BENCHMARKING: STARTUPS/SMES, 2025 370
17.6.5.1 Detailed list of key startups/SMEs 370
17.6.5.2 Competitive benchmarking of key startups/SMEs 372
17.7 COMPANY VALUATION & FINANCIAL METRICS 373
17.7.1 FINANCIAL METRICS 373
17.7.2 COMPANY VALUATION 373
17.8 BRAND/PRODUCT COMPARISON 374
17.9 COMPETITIVE SCENARIO 375
17.9.1 PRODUCT LAUNCHES 375
17.9.2 DEALS 376
17.9.3 EXPANSIONS 377
18 COMPANY PROFILES 378
18.1 KEY PLAYERS 378
18.1.1 SARTORIUS AG 378
18.1.1.1 Business overview 378
18.1.1.2 Products offered 379
18.1.1.3 Recent developments 381
18.1.1.3.1 Product launches 381
18.1.1.3.2 Deals 381
18.1.1.3.3 Expansions 382
18.1.1.4 MnM view 383
18.1.1.4.1 Key strengths 383
18.1.1.4.2 Strategic choices 383
18.1.1.4.3 Weaknesses & competitive threats 383
18.1.2 DANAHER CORPORATION 384
18.1.2.1 Business overview 384
18.1.2.2 Products offered 386
18.1.2.3 Recent developments 388
18.1.2.3.1 Product launches 388
18.1.2.3.2 Deals 388
18.1.2.3.3 Expansions 389
18.1.2.4 MnM view 390
18.1.2.4.1 Right to win 390
18.1.2.4.2 Strategic choices 390
18.1.2.4.3 Weaknesses & competitive threats 390
18.1.3 THERMO FISHER SCIENTIFIC INC. 391
18.1.3.1 Business overview 391
18.1.3.2 Products offered 393
18.1.3.3 Recent developments 394
18.1.3.3.1 Product launches 394
18.1.3.3.2 Deals 395
18.1.3.3.3 Expansions 396
18.1.3.4 MnM view 396
18.1.3.4.1 Right to win 396
18.1.3.4.2 Strategic choices 397
18.1.3.4.3 Weaknesses & competitive threats 397
18.1.4 MERCK KGAA 398
18.1.4.1 Business overview 398
18.1.4.2 Products offered 400
18.1.4.3 Recent developments 401
18.1.4.3.1 Product launches 401
18.1.4.3.2 Deals 401
18.1.4.3.3 Expansions 402
18.1.4.4 MnM view 403
18.1.4.4.1 Right to win 403
18.1.4.4.2 Strategic choices 403
18.1.4.4.3 Weaknesses & competitive threats 403
18.1.5 AVANTOR, INC. 404
18.1.5.1 Business overview 404
18.1.5.2 Products offered 406
18.1.5.3 Recent developments 407
18.1.5.3.1 Deals 407
18.1.5.3.2 Expansions 407
18.1.6 REPLIGEN CORPORATION 408
18.1.6.1 Business overview 408
18.1.6.2 Products offered 410
18.1.6.3 Recent developments 411
18.1.6.3.1 Deals 411
18.1.6.3.2 Expansions 411
18.1.7 GETINGE AB 412
18.1.7.1 Business overview 412
18.1.7.2 Products offered 414
18.1.7.3 Recent developments 415
18.1.7.3.1 Product launches 415
18.1.7.3.2 Deals 415
18.1.7.3.3 Expansions 416
18.1.8 EPPENDORF SE 417
18.1.8.1 Business overview 417
18.1.8.2 Products offered 418
18.1.8.3 Recent developments 419
18.1.8.3.1 Deals 419
18.1.8.3.2 Expansions 419
18.1.9 PARKER HANNIFIN CORPORATION 420
18.1.9.1 Business overview 420
18.1.9.2 Products offered 422
18.1.10 ENTEGRIS 423
18.1.10.1 Business overview 423
18.1.10.2 Products offered 425
18.1.11 SAINT-GOBAIN 426
18.1.11.1 Business overview 426
18.1.11.2 Products offered 427
18.1.11.3 Recent developments 428
18.1.11.3.1 Product launches 428
18.1.11.3.2 Expansions 428
18.1.12 CORNING INCORPORATED 429
18.1.12.1 Business overview 429
18.1.12.2 Products offered 430
18.1.13 LONZA 431
18.1.13.1 Business overview 431
18.1.13.2 Products offered 432
18.1.13.3 Recent developments 433
18.1.13.3.1 Deals 433
18.1.14 TECNIC PROCESS EQUIPMENT MANUFACTURING, S.L. 434
18.1.14.1 Business overview 434
18.1.14.2 Products offered 434
18.1.14.3 Recent developments 435
18.1.14.3.1 Product launches 435
18.1.14.3.2 Expansions 435
18.1.15 ZACROS CORPORATION 436
18.1.15.1 Business overview 436
18.1.15.2 Products offered 437
18.2 OTHER PLAYERS 438
18.2.1 ADOLF KÜHNER AG 438
18.2.2 OMNIBRX BIOTECHNOLOGIES PVT LTD. 439
18.2.3 NEW HORIZON BIOTECHNOLOGY, INC. 440
18.2.4 PBS BIOTECH, INC. 441
18.2.5 BBI-BIOTECH GMBH 442
18.2.6 ABEC, INC. 443
18.2.7 ESCO LIFESCIENCES GROUP 444
18.2.8 DISTEK, INC. 445
18.2.9 SATAKE MULTIMIX CORPORATION 446
18.2.10 CELL CULTURE COMPANY, LLC 447
18.2.11 MICRODIGITAL CO., LTD. 448
18.2.12 BIONET 449
18.2.13 MEISSNER FILTRATION PRODUCTS, INC. 450
18.2.14 SOLIDA BIOTECH GMBH 451
18.2.15 G&G TECHNOLOGIES, INC. 451
18.2.16 PHARMNXT BIOTECH 452
18.2.17 TOFFLON LIFE SCIENCE CO., LTD. 452
18.2.18 SHANGHAI LEPURE BIOTECH CO., LTD. 453
19 RESEARCH METHODOLOGY 454
19.1 RESEARCH DATA 454
19.1.1 SECONDARY DATA 455
19.1.1.1 Key secondary sources 455
19.1.1.2 Key data from secondary research 455
19.1.2 PRIMARY DATA 456
19.1.2.1 Key primary participants 456
19.1.2.2 Breakdown of primary interviews 456
19.1.2.3 Key data from primary sources 456
19.2 MARKET SIZE ESTIMATION 457
19.2.1 GLOBAL SINGLE-USE BIOREACTORS MARKET ESTIMATION, 2025 457
19.2.1.1 Approach 1: Company revenue analysis-based estimation
(bottom-up) 457
19.2.1.2 Approach 2: Primary research 459
19.2.1.2.1 Key industry insights 459
19.2.1.3 Approach 3: MnM repository analysis 459
19.2.2 SEGMENTAL MARKET SIZE ESTIMATION, 2025 460
19.3 MARKET GROWTH RATE PROJECTIONS 462
19.4 DATA TRIANGULATION 464
19.5 RESEARCH ASSUMPTIONS 465
19.6 RESEARCH LIMITATIONS & RISK ASSESSMENT 466
20 APPENDIX 467
20.1 DISCUSSION GUIDE 467
20.2 KNOWLEDGESTORE: MARKETSANDMARKETS’ SUBSCRIPTION PORTAL 472
20.3 CUSTOMIZATION OPTIONS 474
20.4 RELATED REPORTS 475
20.5 AUTHOR DETAILS 476